Patient handout

NSTEMI — diabetic silent / atypical (autonomic neuropathy; anginal-equivalent presentation)

PRODUCTION

1. Your condition

This handout is for nstemi — diabetic silent / atypical (autonomic neuropathy; anginal-equivalent presentation). Your care team identified this based on: unexplained dyspnea or fatigue in t2dm patient with microalbuminuria, retinopathy, or peripheral neuropathy — anginal-equivalent silent nstemi suspect; low threshold for serial hstn + ecg.

Other reasons your team may use this plan: nausea, diaphoresis, or syncope in diabetic patient — anginal-equivalent presentation per canto jama 2012 pmid 22340557; women with diabetes even more likely atypical; unexplained hypoglycemia in diabetic patient (counter-regulatory failure during ischemia) — silent mi consideration; diabetic patient with resting tachycardia >100, orthostatic sbp drop ≥20, or known can markers presenting with anginal equivalent — high pre-test probability silent ischemia.

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
aspirin	162-325 mg load → 81 mg	PO chewed	load once → 81 mg daily lifelong	Universal — ACC/AHA 2025 ACS Class I; ISIS-2 mortality benefit; lifelong post-MI
ticagrelor	180 mg load → 90 mg BID	PO	BID × 12 mo	PLATO PMID 19717846 — net benefit preserved/amplified in DM subgroup; preferred P2Y12 in DM-ACS per ACC/AHA 2025
clopidogrel	300-600 mg load → 75 mg	PO	daily × 12 mo	Alternative if ticagrelor intolerance or HBR; CURE trial backbone
unfractionated_heparin	60 U/kg IV bolus + 12 U/kg/h infusion	IV	bolus + infusion at PCI; aPTT 50-70	AHA 2025 ACS Class I peri-PCI AC; UFH preferred for short half-life + reversibility
enoxaparin	1 mg/kg SC q12h (1 mg/kg q24h if CrCl 15-30; HOLD if CrCl <15)	SC	q12h or q24h per CrCl until cath or end of hospitalisation	ESSENCE; renal dose-adjust mandatory in diabetic nephropathy; switch to UFH at PCI
atorvastatin	80 mg daily	PO	daily lifelong	PROVE-IT PMID 15007110 — high-intensity statin lifelong; LDL target <70 (or <55 very-high-risk per ESC 2023)
lisinopril	5 mg daily titrate	PO	daily	HOPE PMID 10639539 — ramipril CV benefit in DM; ACEi reduces albuminuria + slows nephropathy progression; ACC/AHA 2025 + ADA 2026 Class I in DM-ACS
metoprolol_tartrate	25 mg BID titrate (start lower if EF reduced)	PO	BID	CAPRICORN + ACC/AHA 2025 Class I post-MI BB; cardioselective preferred to minimize hypoglycemia masking
dapagliflozin	10 mg daily (HOLD peri-procedural and if NPO/sepsis — DKA risk)	PO	daily post-stabilization	DAPA-MI PMID 38320150 — SGLT2i post-MI cardio-renal benefit; DECLARE PMID 30415602 + EMPA-REG PMID 26378978; ADA 2026 Class I in DM with CV/renal disease; HOLD if NPO/sepsis (DKA risk)
liraglutide	0.6 mg SC daily titrate to 1.2-1.8 mg	SC	daily	LEADER PMID 27295427 — liraglutide CV benefit in T2DM; ADA 2026 + ACC/AHA 2025 Class I in T2DM-ACS post-stabilization; weight + CV benefit
metformin	HOLD peri-cath × 48 h; resume 500 mg BID titrate to 1000 mg BID if eGFR ≥30 stable post-cath	PO	BID	FDA label — HOLD peri-contrast (lactic acidosis risk); resume post-cath if renal stable; first-line T2DM agent per ADA 2026
insulin_regular	IV infusion 0.05-0.1 U/kg/h titrate to glucose 140-180	IV	continuous	DIGAMI PMID 9099043 + HI-5 PMID 16936138 — insulin glucose-control improves DM-ACS outcomes; ADA 2026 inpatient target 140-180 in critically ill
sacubitril-valsartan	24/26 mg BID titrate (start at ≥36 h post-ACEi, SBP ≥100)	PO	BID	PIONEER-HF PMID 30403955 + ACC/AHA 2022 HF Class I — initiate ARNI if HFrEF persists post-MI
eplerenone	25 mg daily (HOLD if K >5 or eGFR <30)	PO	daily	EPHESUS post-MI MRA Class I; particular benefit in DM substrate

Plan: Diabetic silent NSTEMI phenotype — standard NSTE-ACS bundle plus diabetes-specific glycemic management, peri-procedural metformin/SGLT2i hold, and post-stabilization SGLT2i + GLP-1 RA cardio-renal benefit

3. When to call your provider

Contact your care team if any of the following happen:

Recurrent chest pain or anginal-equivalent → ED + reassess
BARC 2+ bleed → de-escalate DAPT immediately
NYHA worsening to III+ → expedite cardiology re-eval + echo
Functional decline / new neurologic deficit → comprehensive re-eval
Worsening A1c → endo + regimen escalation

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

SBP <90 + lactate ≥2 + hypoperfusion in diabetic NSTEMI patient — pain perception blunted by CAN; may present as unexplained hypotension + organ dysfunction without classic chest pain; lower threshold for shock workup(life-threatening)
Glucose >600 + osmolality >320 + altered mental status in diabetic NSTEMI patient — HHS overlap; high mortality without aggressive volume + insulin + electrolyte management(life-threatening)
Glucose <54 + altered mental status / seizure / cardiac event in diabetic NSTEMI patient — counter-regulatory failure during ischemia; may itself be presenting feature of silent MI
New murmur, pulmonary edema, RV failure in diabetic NSTEMI — papillary muscle rupture, VSD, free-wall rupture; mortality >50% without surgical correction(life-threatening)

5. Follow-up

Cardiology + endocrinology joint follow-up at 1, 4, 12 wks; heart pumping strength (LVEF) re-echo at 40-90 d for ICD eligibility (MADIT-II EF ≤30); cardiac rehab Class I per ACC/AHA 2025 with diabetes-specific glycemic monitoring; intensified secondary prevention (high-intensity statin lifelong, BP <130/80, A1c 7-7.5% individualized per ADA 2026, SGLT2i/GLP-1 RA cardio-renal); annual eye + foot + microalbuminuria screening

6. Sources

Guideline: 2025 ACC/AHA ACS Guideline (Rao) — diabetes ACS subgroup; ADA 2026 Standards of Care; ESC 2023 NSTE-ACS (Byrne, PMID 37622670); 4th UDMI 2018 (Thygesen Circulation 2018, PMID 30153967)